Xiangxue Pharmaceutical
Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of modern Chinese medicine in China. The company provides ban lan gen granules, flu-over liquid, juhong cough-off liquid, and juhong cough-off decoction; chinese herbal, such as huazhou citri grandis, goji berry, chrysanthemum, and rose dried buds; beverages, including king sarsae, asia sarsae, diet s… Read more
Xiangxue Pharmaceutical (300147) - Net Assets
Latest net assets as of September 2025: CN¥1.10 Billion CNY
Based on the latest financial reports, Xiangxue Pharmaceutical (300147) has net assets worth CN¥1.10 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.36 Billion) and total liabilities (CN¥6.27 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.10 Billion |
| % of Total Assets | 14.92% |
| Annual Growth Rate | 12.6% |
| 5-Year Change | -66.17% |
| 10-Year Change | -59.42% |
| Growth Volatility | 76.26 |
Xiangxue Pharmaceutical - Net Assets Trend (2007–2024)
This chart illustrates how Xiangxue Pharmaceutical's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Xiangxue Pharmaceutical (2007–2024)
The table below shows the annual net assets of Xiangxue Pharmaceutical from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.44 Billion | -37.80% |
| 2023-12-31 | CN¥2.31 Billion | -17.92% |
| 2022-12-31 | CN¥2.82 Billion | -25.00% |
| 2021-12-31 | CN¥3.76 Billion | -11.64% |
| 2020-12-31 | CN¥4.25 Billion | +3.44% |
| 2019-12-31 | CN¥4.11 Billion | +2.48% |
| 2018-12-31 | CN¥4.01 Billion | +3.31% |
| 2017-12-31 | CN¥3.88 Billion | +5.41% |
| 2016-12-31 | CN¥3.68 Billion | +3.90% |
| 2015-12-31 | CN¥3.55 Billion | +89.50% |
| 2014-12-31 | CN¥1.87 Billion | +9.43% |
| 2013-12-31 | CN¥1.71 Billion | +11.29% |
| 2012-12-31 | CN¥1.54 Billion | +8.29% |
| 2011-12-31 | CN¥1.42 Billion | +3.53% |
| 2010-12-31 | CN¥1.37 Billion | +305.96% |
| 2009-12-31 | CN¥337.62 Million | +71.79% |
| 2008-12-31 | CN¥196.54 Million | +2.66% |
| 2007-12-31 | CN¥191.45 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Xiangxue Pharmaceutical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2623.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥661.28 Million | 62.69% |
| Other Comprehensive Income | CN¥86.44 Million | 8.19% |
| Other Components | CN¥2.14 Billion | 203.19% |
| Total Equity | CN¥1.05 Billion | 100.00% |
Xiangxue Pharmaceutical Competitors by Market Cap
The table below lists competitors of Xiangxue Pharmaceutical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VOLEX PLC LS -25
F:64K
|
$593.46 Million |
|
Wetown Electric Group Co Ltd
SHG:688226
|
$593.61 Million |
|
Konoike Transport Co. Ltd
F:2KT
|
$593.75 Million |
|
Dom Development S.A.
WAR:DOM
|
$593.81 Million |
|
Mister Car Wash, Inc. Common Stock
NASDAQ:MCW
|
$593.28 Million |
|
Dat Xanh Real Estate Service Contructions Corp
VN:DXG
|
$593.23 Million |
|
Hainan Expressway Co Ltd
SHE:000886
|
$593.20 Million |
|
Eramet SA
PA:ERA
|
$593.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Xiangxue Pharmaceutical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,924,701,823 to 1,054,899,213, a change of -869,802,610 (-45.2%).
- Net loss of 858,559,963 reduced equity.
- Dividend payments of 50,549,008 reduced retained earnings.
- Other comprehensive income increased equity by 84,743,970.
- Other factors decreased equity by 45,437,609.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-858.56 Million | -81.39% |
| Dividends Paid | CN¥50.55 Million | -4.79% |
| Other Comprehensive Income | CN¥84.74 Million | +8.03% |
| Other Changes | CN¥-45.44 Million | -4.31% |
| Total Change | CN¥- | -45.19% |
Book Value vs Market Value Analysis
This analysis compares Xiangxue Pharmaceutical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.83x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 20.63x to 5.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.45 | CN¥9.31 | x |
| 2008-12-31 | CN¥0.46 | CN¥9.31 | x |
| 2009-12-31 | CN¥0.81 | CN¥9.31 | x |
| 2010-12-31 | CN¥2.97 | CN¥9.31 | x |
| 2011-12-31 | CN¥2.29 | CN¥9.31 | x |
| 2012-12-31 | CN¥2.47 | CN¥9.31 | x |
| 2013-12-31 | CN¥3.36 | CN¥9.31 | x |
| 2014-12-31 | CN¥2.84 | CN¥9.31 | x |
| 2015-12-31 | CN¥5.38 | CN¥9.31 | x |
| 2016-12-31 | CN¥5.14 | CN¥9.31 | x |
| 2017-12-31 | CN¥5.25 | CN¥9.31 | x |
| 2018-12-31 | CN¥5.47 | CN¥9.31 | x |
| 2019-12-31 | CN¥5.34 | CN¥9.31 | x |
| 2020-12-31 | CN¥5.52 | CN¥9.31 | x |
| 2021-12-31 | CN¥4.47 | CN¥9.31 | x |
| 2022-12-31 | CN¥3.65 | CN¥9.31 | x |
| 2023-12-31 | CN¥2.92 | CN¥9.31 | x |
| 2024-12-31 | CN¥1.60 | CN¥9.31 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Xiangxue Pharmaceutical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -81.39%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -46.19%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 7.11x
- Recent ROE (-81.39%) is below the historical average (-2.15%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 17.20% | 11.92% | 0.47x | 3.09x | CN¥12.89 Million |
| 2008 | 19.74% | 12.19% | 0.53x | 3.03x | CN¥17.74 Million |
| 2009 | 15.88% | 13.45% | 0.54x | 2.18x | CN¥18.86 Million |
| 2010 | 5.51% | 14.45% | 0.28x | 1.37x | CN¥-60.56 Million |
| 2011 | 5.99% | 13.55% | 0.32x | 1.38x | CN¥-55.92 Million |
| 2012 | 7.22% | 13.38% | 0.27x | 1.99x | CN¥-41.16 Million |
| 2013 | 9.86% | 12.55% | 0.36x | 2.16x | CN¥-2.30 Million |
| 2014 | 11.28% | 12.91% | 0.42x | 2.06x | CN¥22.41 Million |
| 2015 | 5.20% | 12.11% | 0.31x | 1.37x | CN¥-163.47 Million |
| 2016 | 1.94% | 3.55% | 0.23x | 2.35x | CN¥-273.64 Million |
| 2017 | 1.90% | 3.01% | 0.23x | 2.73x | CN¥-280.25 Million |
| 2018 | 1.65% | 2.25% | 0.29x | 2.51x | CN¥-286.62 Million |
| 2019 | 2.19% | 2.75% | 0.33x | 2.43x | CN¥-272.33 Million |
| 2020 | 2.72% | 3.20% | 0.31x | 2.70x | CN¥-263.23 Million |
| 2021 | -23.37% | -23.18% | 0.26x | 3.86x | CN¥-983.02 Million |
| 2022 | -22.04% | -24.24% | 0.23x | 3.89x | CN¥-770.57 Million |
| 2023 | -20.21% | -16.92% | 0.28x | 4.30x | CN¥-581.43 Million |
| 2024 | -81.39% | -46.19% | 0.25x | 7.11x | CN¥-964.05 Million |
Industry Comparison
This section compares Xiangxue Pharmaceutical's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Xiangxue Pharmaceutical (300147) | CN¥1.10 Billion | 17.20% | 5.70x | $593.40 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |